GLP-1 Market
LLY $1208.74 ▲ +3.6% NVO $38.12 ▲ +0.2% PFE $29.21 ▲ +3.0% VKTX $25.47 ▼ -4.4% KLRA $10.74 ▼ -0.3% GPCR $21.88 ▼ -1.9% RHHBY $55.67 ▲ +3.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Acoramidis

Company
Eidos Therapeutics, a BridgeBio company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
8 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

8 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for Acoramidis and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06563895

    Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

    Not yet reported Eidos Therapeutics, a BridgeBio company 587 participants Est. completion 2032-12 104 sites Stand-alone
    Other conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
    View official trial listing →
  • Recruiting NCT NCT07196839

    Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

    University of Texas Southwestern Medical Center 50 participants Est. completion 2027-03 1 site
    Other conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
    View official trial listing →
  • Recruiting NCT NCT07235462

    A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

    Bayer 2000 participants Est. completion 2028-04-30 17 sites
    Other conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    View official trial listing →
  • Recruiting NCT NCT07298044

    A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

    Not yet reported Bayer 50 participants Est. completion 2027-07-15 26 sites Stand-alone
    Other conditions: Transthyretin Amyloid Cardiomyopathy
    View official trial listing →
  • Recruiting NCT NCT07306949

    Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

    Not yet reported Alexion Pharmaceuticals, Inc. 200 participants Est. completion 2028-03-31 16 sites Stand-alone
    Other conditions: Transthyretin-type Cardiac Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07695701

    Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

    Not yet reported Eidos Therapeutics, a BridgeBio company 150 participants Est. completion 2030-11 1 site Stand-alone
    Other conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07766135

    Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis

    University of Messina 70 participants Est. completion 2028-01 1 site
    Other conditions: Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis, Cardiomyopathies, Wild-Type Transthyretin Cardiac Amyloidosis, Hereditary Transthyretin Amyloidosis (ATTRv)
    View official trial listing →
  • Recruiting NCT NCT07791160

    Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy

    Bayer 500 participants Est. completion 2028-12-31 1 site
    Other conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    View official trial listing →
  • Completed NCT NCT03294707

    Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

    Not yet reported Eidos Therapeutics, a BridgeBio company 56 participants Est. completion 2018-05-18 1 site Stand-alone
    Other conditions: Amyloid Cardiomyopathy, Transthyretin-Related
    View official trial listing →
  • Completed NCT NCT03458130

    Study of AG10 in Amyloid Cardiomyopathy

    Not yet reported Eidos Therapeutics, a BridgeBio company 49 participants Est. completion 2018-10-05 13 sites
    Other conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
    View official trial listing →
  • Terminated NCT NCT03536767

    Open-Label Study of AG10 in Patients With Cardiomyopathy

    Not yet reported Eidos Therapeutics, a BridgeBio company 47 participants Est. completion 2025-09-15 9 sites Stand-alone
    Other conditions: Amyloid Cardiomyopathy
    View official trial listing →
  • Completed NCT NCT03860935

    Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

    Not yet reported Eidos Therapeutics, a BridgeBio company 632 participants Est. completion 2023-05-11 104 sites Stand-alone
    Other conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
    View official trial listing →
  • Withdrawn NCT NCT04418024

    Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

    Not yet reported Eidos Therapeutics, a BridgeBio company Est. completion 2024-04-30 1 site Stand-alone
    Other conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
    View official trial listing →
  • Completed NCT NCT04610138

    Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

    Not yet reported Clene Nanomedicine 296 participants Est. completion 2022-10-20 5 sites
    Other conditions: Covid19
    View official trial listing →
  • Completed NCT NCT04622046

    A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

    Not yet reported Alexion Pharmaceuticals, Inc. 25 participants Est. completion 2025-08-21 11 sites
    Other conditions: Symptomatic Transthyretin Amyloid Cardiomyopathy
    View official trial listing →
  • Completed NCT NCT04769479

    A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

    Not yet reported Eidos Therapeutics, a BridgeBio company 14 participants Est. completion 2021-09-03 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Withdrawn NCT NCT04882735

    Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

    Not yet reported Eidos Therapeutics, a BridgeBio company Est. completion 2026-10 Stand-alone
    Other conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
    View official trial listing →
  • Completed NCT NCT04958135

    Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

    Not yet reported Alexion Pharmaceuticals, Inc. 18 participants Est. completion 2021-08-04 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT04988386

    Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

    Not yet reported Eidos Therapeutics, a BridgeBio company 389 participants Est. completion 2028-05-15 72 sites Stand-alone
    Other conditions: Amyloid Cardiomyopathy, Transthyretin-Related
    View official trial listing →
  • Not yet recruiting NCT NCT07116473

    To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

    Not yet reported Eidos Therapeutics, a BridgeBio company 250 participants Est. completion 2037-12 Stand-alone
    Other conditions: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Acoramidis, Attruby, AG10

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.